Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors
- Authors
- Shin, SJ[Shin, Seung Jea]; Kim, T[Kim, Taejin]; Sung, HH[Sung, Hyun Hwan]; Jeon, HG[Jeon, Hwang Gyun]; Jeong, BC[Jeong, Byong Chang]; Park, SH[Park, Se Hoon]; Jeon, SS[Jeon, Seong Soo]; Lee, HM[Lee, Hyun Moo]; Choi, HY[Choi, Han Yong]; Seo, SI[Seo, Seong Il]; Kang, M[Kang, Minyong]
- Issue Date
- Dec-2019
- Publisher
- CIG MEDIA GROUP, LP
- Keywords
- Early death; Metastatic renal cell carcinoma; Predictive model; Survival; Tyrosine kinase inhibitor
- Citation
- CLINICAL GENITOURINARY CANCER, v.17, no.6, pp.E1137 - E1146
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL GENITOURINARY CANCER
- Volume
- 17
- Number
- 6
- Start Page
- E1137
- End Page
- E1146
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/8044
- DOI
- 10.1016/j.clgc.2019.07.014
- ISSN
- 1558-7673
- Abstract
- We reviewed the records of 462 patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors and developed 2 novel prognostic models that can significantly predict early death less than 1 year in patients with metastatic renal cell carcinoma after receiving first-line tyrosine kinase inhibitors. Background: We aimed to develop a modified International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model that can predict early death less than 1 year in patients with metastatic renal cell carcinoma (mRCC) after receiving first-line tyrosine kinase inhibitors (TKIs). Patients and Methods: We retrospectively reviewed records of patients with mRCC treated with first-line TKIs at our institution between 2007 and 2012. The primary endpoint was the rate of early death within 1 year after first-line TKI administration. We determined statistically significant factors predicting early death by performing multiple logistic regression. The modified IMDC model 1 was developed using new variables in addition to the risk criteria of the IMDC model, and model 2 was developed using new variables irrespective of the risk classification of IMDC model. Results: Early mortality within 1 year of first-line TKI treatment was 19.7% (n = 98) in 462 patients. Although the C-index of the IMDC model for early death was 0.655, the C-index of model 1, which includes 5 variables (previous nephrectomy, body mass index, multiple metastases, previous meta-stasectomy, and serum albumin level) in addition to the Heng criteria, was 0.823. The C-index of model 2, which includes 7 variables (hemoglobin, neutrophil level, and the 5 variables of model 1) was 0.822. Of note, there was no significant difference in net reclassification index between the 2 models. Conclusion: This is the first study suggesting novel prediction models for early death less than 1 year in patients with mRCC treated with first-line TKI.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.